9% infuzní roztok

DRUG2 trials

Sponsors

Fakultni Nemocnice Hradec Kralove, Ever Neuro Pharma GmbH

Conditions

Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)Ischemic stroke

Phase 2

CERICA - CERebrolysin In CADASIL - A randomized, double-blind, single-centre, two-period cross-over, placebo-controlled trial on safety and efficacy in patients with genetically proven CADASIL

RecruitingCTIS2024-513828-42-00

Ever Neuro Pharma GmbHCerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)

Start: 2023-11-29Target: 30Updated: 2024-09-19

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx with Low-Dose Albumin Administration (MOZEG)

Not yet recruitingCTIS2023-509261-20-00

Fakultni Nemocnice Hradec KraloveIschemic stroke

Target: 100Updated: 2025-03-26